Stay updated on Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page.

Latest updates to the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page's revision label was updated from v3.5.2 to v3.5.3, indicating a newer metadata version; this change does not alter study details or visible content.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedSite version updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded Squamous cell carcinoma of the head and neck to the study's listed conditions.SummaryDifference0.1%

- Check57 days agoChange DetectedThe revision label on the page was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded Hepatocellular carcinoma to the Conditions section and included the Genetic and Rare Diseases Information Center as a Resources link.SummaryDifference0.2%

- Check71 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page.